Slide 1: Discover. Innovation
DISCOVER. INNOVATION
Slide 2: Disclaimer and forward-looking statements
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented
Slide 3: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. *
Slide 4: Discover. Elron
DISCOVER. ELRON
Slide 5: Operational holding company in the VC space
OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZE IN MEDICAL DEVICE TECHNOLOGIES WITHSIGNIFICANT EXIT POTENTIAL +WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS +WE INVEST PRIMARILY IN EARLY STAGE COMPANIES +WE RELY ONA PROVEN STRATEGY
Slide 6: Performance in 2016
PERFORMANCE IN 2016: 114 20 59 4 269 * Including RDC * 26
Slide 7: Holdings in companies
1 Includes Elron’s direct holdings and its effective indirect holdings through RDC and RDSeed. Includes investments made after June 30, 2016.2 Includes Elron’s balance and 50.1% of RDC’s balance.3 The above financial data are based on publicly available information and do not represent a valuation,
Slide 8: Discover. BrainsGate
DISCOVER. BRAINSGATE
Slide 9: Our investment: $29M, our holding: 30%
OUR INVESTMENT:$29M OUR HOLDING:30% *
Slide 10: Stroke statistics
Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2015; BrainsGate website: http://brainsgate.com/eng/page.php?id=3&instance_id=9. *
Slide 11: Stroke cost and outcomes
Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. mRS Average Lifetime Cost Per Stroke Patient Sources: Samsa et al, Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Compre
Slide 12: Thrombolysis treatment rates
Source: American Heart Association: Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals, Schwamm, Circ Cardiovasc Qual Outcomes. 2013;6:543-549. *
Slide 13: Stroke treatment approaches
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION Sources: Adams HP, et al (2003) Stroke 34, 1056-83; del Zoppo GJ, et al (2009) Stroke 40, 2945-48. *
Slide 14: Clot retrieval trial evidence
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION Sources: Broderick JP, et al (2013) New England Journal of Medicine 368(10), 893-903; Ciccone A, et al (2013) New England Journal of Medicine 368(10), 904-13; Kidwell CS, et al (2013) New England Journal of Medicine 368(10), 914-23; Be
Slide 15: Electrical stimulation treatment
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION *
Slide 16: ISS system components
BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulationTransmitter = emits RF waves which energize the implantImplant = deliver
Slide 17: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 18: Discover. Pocared
DISCOVER. POCARED
Slide 19: Our investment: $64M, our holding: 67%
OUR INVESTMENT:$64M OUR HOLDING:67% *
Slide 20: Microbiology testing by culturing bacteria
Since the 19th century, microbiology testing has been done by culturing bacteria in petri dishes Expensive: Requires reagents and skilled lab techniciansManual: Prone to human error, limited throughputInefficient: Large lab footprintLengthy: Diagnosis that relies on culturing bacteria to reach suffi
Slide 21: Antibiotic resistance
The use of antibiotics is the single most important factor leading to antibiotic resistance around the worldAntibiotics are among the most commonly prescribed drugsUp to 50% of all the antibiotics prescribed are not needed or are not optimally effective as prescribed penicillin 1943 1940 tetracyclin
Slide 22: Microbiology testing market sources
Sources: Bourbeau PP and Ledeboer NA (2013) Journal of Microbiology 51(6), 1658-65; Kaplan RL and Burgess TE (2010) Journal of Microbiology & Biology Education 11(2), 140-43; Novak SM and Marlowe EM (2013) Clinics in Laboratory Medicine 33, 567-88. *
Slide 23: P-1000 Analyzer
The Analyzer employs algorithms that determine which wavelength to choose, and detect the organism’s “optical fingerprint” P-1000 Analyzer Sample Processor User interface The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory appro
Slide 24: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 25: Pocared data
Source: Pocared data. * This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 26: Discover. CartiHeal
DISCOVER. CARTIHEAL
Slide 27: Our investment: $12M, our holding: 35%
OUR INVESTMENT:$12M OUR HOLDING:35% *
Slide 28: Cartilage damage and osteoarthritis
* Cartilage does not possess spontaneous healing potential There are no treatments that halt the progression of osteoarthritis (OA) Sources: CDC website: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm, http://www.cdc.gov/nchs/fastats/inpatient-surgery.htm; Losina E, et al (2015) Arthritis Ca
Slide 29: Agili-C results
* 12 weeks post-op 6 weeks post-op 3 weeks post-op The Agili-C is investigational in the U.S., and CE-marked in the EU.
Slide 30: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 31: Discover. Cloudyn
DISCOVER. CLOUDYN
Slide 32: Our investment: $6M, our holding: 40%
OUR INVESTMENT:$6M OUR HOLDING:40% *
Slide 33: Hybrid cloud management challenges
* Source: ScienceLogic Annual Report on Hybrid IT Trends, http://www.sciencelogic.com/cloud-adoption-survey/ Migrating the proper workloads and building the right mix of clouds is tough Enterprises are struggling to build a single, accurate picture to govern cloud resource usage Cost and performance
Slide 34: Cloudyn visibility, accountability, optimization
* VISIBILITY Cloudyn’s solutions enable enterprises to gain granular, real-time visibility into consumption, cost & performance of multi-platform hybrid clouds ACCOUNTABILITY Cloudyn empowers enterprise-wide cloud accountability through accurate and reliable cost allocation and chargeback OPTIMIZATI
Slide 35: Cloudyn raises $4M from Infosys
CLOUDYN RAISES $4M FROM INFOSYS Cloudyn raises $4m from India's NPS MWY TD V7 YN 4 NOMIN | TNT Infosys pya nn EEE ©ve v3 RIED one) N77 O2IW7 MI Cloudyn .01NA NW APIA Infosys NAINA IT-A NDY ‘yaa men man (AWA pyA AMSA wy NINH WOO TTY OATW pYA awn nee a HmaynaHor9A ‘ann eR man sorminro4 Vat ttn 4 ayn N
Slide 36: Discover. OpenLegacy
DISCOVER. OPENLEGACY
Slide 37: Our investment: $3.1M, our holding: 37%
OUR INVESTMENT:$3.1M OUR HOLDING:37% *
Slide 38: Legacy IT challenges
* Sources: United States Government Accountability Office, Information Technology: Additional Actions and Oversight Urgently Needed to Reduce Waste and Improve Performance in Acquisitions and Operations, GAO-15-675T, Jun 10, 2015, http://www.gao.gov/assets/680/670745.pdf; Tenemos, Banks are st
Slide 39: OpenLegacy revolutionizes legacy modernization
* OPENLEGACY REVOLUTIONIZES LEGACY MODERNIZATION, OFFERING INDEPENDENCE FROM EXPENSIVE VENDORS, AND ELIMINATING HIGH COSTS AND HIGH RISK Reduced time to market (TTM) A fraction of the cost (TCO) Ensures success of digital transformation
Slide 40: Our investment: $0.75M, our holding: 27%
* OUR INVESTMENT:$0.75M OUR HOLDING:27%* * 27% after the funding round will be completed; currently 16%.
Slide 41: Elron. Opportunity. Thank you.
ELRON. OPPORTUNITY Thank you.